awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-CA589B9E-4FC1-4613-8637-0EB639E201CA
Q33400687-CA589B9E-4FC1-4613-8637-0EB639E201CA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-CA589B9E-4FC1-4613-8637-0EB639E201CA
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2093
Q33400687-CA589B9E-4FC1-4613-8637-0EB639E201CA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-CA589B9E-4FC1-4613-8637-0EB639E201CA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
256eeff384f48a1f6d966af735f5aff466ea87bf
P1545
4
http://www.w3.org/2001/XMLSchema#string
P2093
Ramesh K Ramanathan
http://www.w3.org/2001/XMLSchema#string